.png)
.svg)
The European Commission has proposed a targeted revision of the Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) aimed at supporting innovation while reducing unnecessary administrative burden. The initiative responds to persistent capacity constraints, regulatory bottlenecks, and disproportionate compliance obligations that have affected market access, particularly for innovative and software-driven devices.
Impact on Technical Documentation
A key focus of the proposal is streamlining technical documentation requirements without compromising safety or performance. The revisions seek greater proportionality in evidence expectations, improved reuse of existing data, clearer rules on legacy devices, and reduced duplication across conformity assessments. For software and AI-enabled devices, the Commission signals a need for clearer alignment between design documentation, lifecycle updates, and post-market evidence generation.
Implications for Manufacturers
Manufacturers may benefit from reduced rework of technical files, more predictable notified body interactions, and improved regulatory timelines. However, companies will still need robust design controls, traceability, and post-market surveillance systems to demonstrate compliance, particularly for software-intensive devices.
Implementation Challenges
Manufacturers may face transitional complexity as revised rules are interpreted and implemented unevenly across notified bodies. Software updates, cybersecurity controls, and AI change management remain challenging, especially where documentation expectations evolve faster than internal QMS processes.
Regulatory Pitfalls in Software Oversight
For regulators, key pitfalls include assessing complex software architectures, evaluating adaptive algorithms, ensuring consistency across notified bodies, and balancing innovation with patient safety in rapidly iterating technologies.
For more information, visit https://eemedicals.com/
.svg)
.svg)
.svg)